-
Citi Reiterates Buy and PT of $49 on Medtronic
Wednesday, May 25, 2011 - 6:41am | 107Citi reiterated its Buy rating on Medtronic (NYSE: MDT). At the same time, Citi left its price target unchanged at $49 after Medtronic announced its quarterly results. In a research report published today, Citi states, "MDT's F4Q11 results weren't as bad as we feared as several new products...
-
Deutsche Bank Reiterates Buy on Medtronic
Wednesday, May 25, 2011 - 6:22am | 138Deutsche Bank reiterated its Buy rating on Medtronic (NYSE: MDT) after the company announced its quarterly results. In a research report published today, Deutsche Bank states, "F4Q sales were in line but EPS of $0.90 was $0.02 below First Call Cons and $0.03 below implied guidance due to Greece...
-
Goldman Sachs Upgrades Boston Scientific To Neutral, Raises PT To $7
Wednesday, May 25, 2011 - 5:38am | 28Goldman Sachs has upgraded Boston Scientific (NYSE: BSX) from Sell to Neutral and has raised the price target from $6.50 to $7.
-
Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Highest Cash
Wednesday, May 25, 2011 - 1:27am | 129Below are the top small-cap diagnostic substances stocks on the NYSE and NASDAQ in terms of cash. Immucor Inc (NASDAQ: BLUD) had $274.68 million in total cash and no debt for the latest quarter. AMAG Pharmaceuticals Inc (NASDAQ: AMAG) had $238.23 million in total cash and no debt for the latest...
-
Options Brief: St. Jude Medical, Inc.
Tuesday, May 24, 2011 - 10:32am | 89Shares of St. Jude Medical, Inc. (NYSE: STJ) are lower on the session by 0.28%, trading at $49.16. Overall put volume is now running at 3.40x the daily average, with 1% of all puts traded being purchases on the offer. 2,023 contracts have traded on the session so far. St. Jude Medical, Inc....
-
News Summary
Tuesday, May 24, 2011 - 9:50am | 272Shares of Valeant Pharmaceuticals International Inc (NYSE: VRX) gained about 3.7% after the company announced its plans to acquire Lithuania-based AB Sanitas for around 314 million euros ($442.9 million) in cash. The transaction also includes 50 million euros of Sanitas debt. The deal is likely to...
-
Smith & Nephew Signs Distribution Agreement for Unique Injectable Bone Void Filler With Graftys
Tuesday, May 24, 2011 - 9:35am | 139Smith & Nephew Orthopaedics (NYSE: SNN) today announces the signing of a distribution agreement with French biotechnology company Graftys. The deal gives Smith & Nephew distribution rights for Graftys' fast-setting, macroporous calcium phosphate bone void filler in the U.S., and potentially...
-
Piper Jaffray Maintains Overweight Rating On Medtronic
Tuesday, May 24, 2011 - 9:31am | 86According to Piper Jaffray, Medtronic (NYSE: MDT) Overweight rating is maintained. Piper Jaffray said that Medtronic reported Q4:F11 results with revenue of $4.295B (+2%) vs consensus of $4.290B. “EPS totaled $0.90 compared to expectations for $0.93. ICDs and spine were again weak, offset by...
-
Earnings Roundup For May 24
Tuesday, May 24, 2011 - 8:47am | 675Medtronic Inc (NYSE: MDT) reported a 19% drop in its fourth quarter net income on Tuesday. Medtronic reported its Q4 profit at $776 million, or $0.72 per share, down from $954 million, or $0.86 per share, in the year-ago period. Excluding restructuring and other costs of $198 million, Medtronic's...
-
EDAP Reports 12.1% Rise In Q1 Revenue
Tuesday, May 24, 2011 - 8:44am | 119EDAP TMS SA (NASDAQ: EDAP) released its results for the first quarter on Tuesday. EDAP reported its total revenue at EUR 4.9 million (USD 6.8 million), up from EUR 4.3 million (USD 5.9 million), in the year-ago quarter. EDAP reported its net income at EUR 213,000 (USD 295,000), or EUR 0.02 per...
-
Medtronic Sees 2012 EPS of $3.43 to $3.50 Including $0.04 to $0.06 Dilution
Tuesday, May 24, 2011 - 8:37am | 104Medtronic, Inc. (NYSE: MDT) today provided its initial revenue outlook and diluted earnings per share guidance for fiscal year 2012. The company expects revenue growth in the range of 1 to 3 percent on a constant currency basis, which is consistent with current growth in the company's markets....
-
Varian Medical Systems Subsidiary Licenses Novel New Drug Designed to Enhance the Effectiveness of Cancer Treatment
Tuesday, May 24, 2011 - 8:03am | 112Centella Therapeutics, Inc., a subsidiary of Varian Medical Systems, Inc. (NYSE: VAR), and Auckland UniServices Ltd. of Auckland, New Zealand, today announced that they have entered into a licensing agreement granting Centella exclusive rights to CEN-209, a novel investigational drug designed to...
-
UPDATE: Medtronic Reports Weaker-Than-Expected Q4 Earnings
Tuesday, May 24, 2011 - 8:01am | 101Medtronic Inc (NYSE: MDT) reported a 19% drop in its fourth-quarter net income on Tuesday. Medtronic reported its Q4 profit at $776 million, or $0.72 per share, down from $954 million, or $0.86 per share, in the year-ago period. Excluding restructuring and other costs of $198 million, Medtronic's...
-
Stryker Receives FDA 510(K) Clearance for Shapematch; Cutting Guides
Tuesday, May 24, 2011 - 8:01am | 69Stryker Orthopaedics, a division of Stryker Corporation (NYSE: SYK), today announced that its ShapeMatch Cutting Guides have been granted 510(k) market clearance by the U.S. Food and Drug Administration for use with the company's Triathlon Total Knee System. The single-use ShapeMatch Cutting Guides...
-
Earnings Scheduled For May 24
Tuesday, May 24, 2011 - 1:04am | 445Avago Technologies Limited (NASDAQ: AVGO) is expected to post its FQ2 EPS at $0.60 on revenue of $554.40 million. TiVo Inc (NASDAQ: TIVO) is projected to report a Q1 loss at $0.31 per share on revenue of $41.98 million. AutoZone Inc (NYSE: AZO) is projected to report its FQ3 EPS at $4.99 on...